XML 61 R39.htm IDEA: XBRL DOCUMENT
v3.22.0.1

License, Collaborative and Employment Agreements and Commitments - Additional Information (Details) - USD ($) |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 23, 2021 | Dec. 30, 2020 | Dec. 23, 2020 | Aug. 07, 2019 | Sep. 05, 2018 | Dec. 05, 2013 | Nov. 30, 2017 | Dec. 19, 2012 | Dec. 19, 2012 | Nov. 28, 2012 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2015
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payments for Other Fees |  |  |  |  |  |  | $ 4,500,000 |  |  |  |  |  |
Cost of Living Adjustments Percentage |  |  | 62.50% |  |  |  |  |  |  |  |  |  |
Fair Value Of Shares Issued |  |  |  |  | $ 285,000 |  |  |  |  |  |  |  |
Operating Lease, Cost |  |  |  |  |  |  |  |  |  |  | $ 280,000 | $ 209,000 |
Operating Lease, Payments |  |  |  |  |  |  |  |  |  |  | 321,000 | 309,000 |
Non Cash Addition of Right of Use Assets |  |  |  |  |  |  |  |  |  |  | $ 538,000 |  |
Operating Lease, Weighted Average Discount Rate, Percent |  |  |  |  |  |  |  |  |  |  | 8.50% |  |
Research and Development Expense |  |  |  |  |  |  |  |  |  |  | $ 7,800,000 | 5,131,000 |
Cedarssinai Medical Center [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number Of Common Stock To Be Issued |  |  |  |  | 50,000 |  |  |  |  |  |  |  |
Number Of Common Stock To Be Held By Related Party |  |  |  |  | 7,480,000 |  |  |  |  |  |  |  |
Cedarssinai Medical Center [Member] | SYN Biomics [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional Number Of Common Stock To Be Issued |  |  |  |  | 2,420,000 |  |  |  |  |  |  |  |
Operating Lease [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Operating Lease, Cost |  |  |  |  |  |  |  |  |  |  |  | 1,300,000 |
Licensing Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Annual payments due under license agreement |  |  |  |  |  |  |  |  | $ 50,000 |  |  |  |
Final payment due under license agreement |  |  |  |  |  |  |  |  | 25,000 |  |  |  |
Payments for Other Fees |  |  |  |  |  | $ 150,000 |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues |  |  |  |  |  | 9,569 |  |  |  |  |  |  |
Patents [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payments for Other Fees |  |  |  |  |  | $ 220,000 |  |  |  |  |  |  |
Steven A. Shallcross |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage |  | 62.00% |  |  |  |  |  |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross |  | 450,000 |  |  |  |  |  |  |  |  |  |  |
Dr. Sliman [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage | 62.50% |  |  |  |  |  |  |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 650,000 |  |  |  |  |  |  |  |  |  |  |  |
Annual Base Salary |  |  | $ 450,000 |  |  |  |  |  |  |  |  |  |
Prev Abr Llc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional Cash Payment for License Agreement |  |  |  |  |  |  |  |  |  | $ 235,000 |  |  |
Unregistered Shares Issued to License Agreement |  |  |  |  |  |  |  |  |  | 17,858 |  |  |
Additional Consideration Payable |  |  |  |  |  |  |  |  |  | 50% in cash and 50% in our stock |  |  |
Options To Be Received Common Stock Shares |  |  |  |  |  |  |  |  |  |  |  |  | 18,724
Phase I Clinical Trials [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  | $ 50,000 |  |  |  |  |
Phase III Clinical Trials [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  | 100,000 |  |  |  |  |
NDA Submission In US [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  | 250,000 |  |  |  |  |
European Medicines Agency Approval [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  | 100,000 |  |  |  |  |
Regulatory Approval In Asian Country [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Payment |  |  |  |  |  |  |  | 100,000 |  |  |  |  |
Stock Purchase Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Expense |  |  |  |  |  |  |  |  |  |  | $ 1,000 | $ 225,000 |
Clinical Trial Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated Research Costs |  |  |  | $ 3,200,000 |  |  |  |  |  |  |  |  |
First Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Research Agreement Fixed Fee |  |  |  |  |  |  |  | 303,287 | 303,287 |  |  |  |
Second Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Research Agreement Fixed Fee |  |  |  |  |  |  |  | 316,438 | 316,438 |  |  |  |
Third Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
License, Collaborative and Employment Agreements and Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Research Agreement Fixed Fee |  |  |  |  |  |  |  | $ 328,758 | $ 328,758 |  |  |  |

X
- Definition The amount of additional cash payment for license agreement. + References No definition available. + Details
Name: | syn_AdditionalCashPaymentForLicenseAgreement
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Description related to additional consideration payable. + References No definition available. + Details
Name: | syn_AdditionalConsiderationPayable
Namespace Prefix: | syn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The additional number of common stock to be issued under stock purchase agreement. + References No definition available. + Details
Name: | syn_AdditionalNumberOfCommonStockToBeIssued
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the information pertaining to cost of living adjustments percentage. + References No definition available. + Details
Name: | syn_CostOfLivingAdjustmentsPercentage
Namespace Prefix: | syn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of estimated research services cost provided. + References No definition available. + Details
Name: | syn_EstimatedResearchCosts
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount represents the fair value of shares issued. + References No definition available. + Details
Name: | syn_FairValueOfSharesIssued
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of annual payments due under the license agreement. + References No definition available. + Details
Name: | syn_LicenseAgreementAnnualPaymentsDue
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of the final payment due under the license agreement. + References No definition available. + Details
Name: | syn_LicenseAgreementFinalPaymentDue
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems
Namespace Prefix: | syn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition A milestone payment is an authority payment made to a contractor which is linked to the contractor delivering a service or commodity such that, should the agreement be terminated at the point of payment. + References No definition available. + Details
Name: | syn_MilestonePayment
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of non cash addition to right of use assets. + References No definition available. + Details
Name: | syn_NonCashAdditionOfRightOfUseAssets
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The additional number of common stock to be held by the related party under stock purchase agreement. + References No definition available. + Details
Name: | syn_NumberOfCommonStockToBeHeldByRelatedParty
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of common stock to be issued under stock purchase agreement. + References No definition available. + Details
Name: | syn_NumberOfCommonStockToBeIssued
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition It Represents options to be received common stock shares reporting period. + References No definition available. + Details
Name: | syn_OptionsToBeReceivedCommonStockShares
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of research and development costs incurred for a fixed-price, all payable in quarterly installments. + References No definition available. + Details
Name: | syn_ResearchAgreementFixedFee
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of shares issued during the period for license agreement. + References No definition available. + Details
Name: | syn_UnregisteredSharesIssuedToLicenseAgreement
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary. + References No definition available. + Details
Name: | us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980 + Details
Name: | us-gaap_OperatingLeaseCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 5 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(1) -URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980 + Details
Name: | us-gaap_OperatingLeasePayments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Weighted average discount rate for operating lease calculated at point in time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (g)(4) -URI http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 55 -Paragraph 53 -URI http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971 + Details
Name: | us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments of cash to employees, including wages and salaries, during the current period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585 + Details
Name: | us-gaap_PaymentsToEmployees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Gross number of share options (or share units) granted during the period. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=syn_SYNBiomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=syn_StevenAShallcrossMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=syn_Dr.SlimanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=syn_PrevAbrLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_PhaseIClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_PhaseIiiClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_NdaSubmissionInUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_EuropeanMedicinesAgencyApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_RegulatoryApprovalInAsianCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=syn_ClinicalTrialAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_FirstYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_SecondYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_ThirdYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |